Skip Navigation

Cardiovascular Research 2007 74(2):304-312; doi:10.1016/j.cardiores.2007.02.023
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by McKoy, G.
Right arrow Articles by Brooks, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McKoy, G.
Right arrow Articles by Brooks, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2007, European Society of Cardiology

Developmental expression of myostatin in cardiomyocytes and its effect on foetal and neonatal rat cardiomyocyte proliferation

Godfrina McKoya,1, Katrina A. Bicknella,1, Ketan Patelb and Gavin Brooksa,*

aCardiovascular Research Group, School of Pharmacy, The University of Reading, PO Box 226, Whiteknights, Reading, RG6 6AP, UK
bSchool of Biological Sciences The University of Reading, PO Box 228, Whiteknights, Reading, RG6 6AJ, UK

* Corresponding author. Tel.: +44 118 378 6565; fax: +44 118 378 6562. Email address: g.brooks{at}reading.ac.uk

Objectives: Myostatin, a member of the transforming growth factor-beta (TGF-β) family, plays a key role in skeletal muscle myogenesis by limiting hyperplastic and hypertrophic muscle growth. In cardiac muscle, myostatin has been shown to limit agonist-induced cardiac hypertrophic growth. However, its role in cardiac hyperplastic growth remains undetermined. The aim of this study was to characterise the expression of myostatin in developing myocardium, determine its effect on cardiomyocyte proliferation, and explore the signalling mechanisms affected by myostatin in dividing cardiomyocytes.

Methods: We used quantitative PCR and Western blotting to study the expression of myostatin in cardiomyocytes isolated from rat myocardium at different developmental ages. We determined the effect of recombinant myostatin on proliferation and cell viability in dividing cardiomyocytes in culture. We analysed myostatin's effect on cardiomyocyte cell cycle progression by flow cytometry and used Western blotting to explore the signalling mechanisms involved.

Results: Myostatin is expressed differentially in cardiomyocytes during cardiac development such that increasing expression correlated with a low cardiomyocyte proliferation index. Proliferating foetal cardiomyocytes, from embryos at 18 days of gestation, expressed low levels of myostatin mRNA and protein, whereas isolated cardiomyocytes from postnatal day 10 hearts, wherein the majority of cardiomyocytes have lost their ability to proliferate, displayed a 6-fold increase in myostatin expression. Our in vitro studies demonstrated that myostatin inhibited proliferation of dividing foetal and neonatal cardiomyocytes. Flow cytometric analysis showed that this inhibition occurs mainly via a block in the G1-S phase transition of the cardiomyocyte cell cycle. Western blot analysis showed that part of the mechanism underpinning the inhibition of cardiomyocyte proliferation by myostatin involves phosphorylation of SMAD2 and altered expressions of the cell cycle proteins p21 and CDK2.

Conclusions: We conclude that myostatin is an inhibitor of cardiomyocyte proliferation with the potential to limit cardiomyocyte hyperplastic growth by altering cardiac cell cycle progression.

KEYWORDS Cardiomyocytes; CDK2; Myostatin; p21; SMAD2; TGF-β

1 These authors contributed equally to this study.

Time for primary review 21 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
E. Lara-Pezzi, L. E. Felkin, E. J. Birks, P. Sarathchandra, K. D. Panse, R. George, J. L. Hall, M. H. Yacoub, N. Rosenthal, and P. J. R. Barton
Expression of Follistatin-Related Genes Is Altered in Heart Failure
Endocrinology, November 1, 2008; 149(11): 5822 - 5827.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Kondas, G. Szlama, M. Trexler, and L. Patthy
Both WFIKKN1 and WFIKKN2 Have High Affinity for Growth and Differentiation Factors 8 and 11
J. Biol. Chem., August 29, 2008; 283(35): 23677 - 23684.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
B. D. Rodgers and D. K. Garikipati
Clinical, Agricultural, and Evolutionary Biology of Myostatin: A Comparative Review
Endocr. Rev., August 1, 2008; 29(5): 513 - 534.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
Y. Oshima, N. Ouchi, K. Sato, Y. Izumiya, D. R. Pimentel, and K. Walsh
Follistatin-Like 1 Is an Akt-Regulated Cardioprotective Factor That Is Secreted by the Heart
Circulation, June 17, 2008; 117(24): 3099 - 3108.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
B.-W. Wang, H. Chang, P. Kuan, and K.-G. Shyu
Angiotensin II activates myostatin expression in cultured rat neonatal cardiomyocytes via p38 MAP kinase and myocyte enhance factor 2 pathway
J. Endocrinol., April 1, 2008; 197(1): 85 - 93.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.